NCT01730157: Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases |
|
|
| Terminated | 1 | 6 | US | ipilimumab, anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody, MDX-010, MDX-CTLA-4, monoclonal antibody CTLA-4, yttrium Y 90 glass microspheres, TheraSphere, laboratory biomarker analysis | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Liver Metastases, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma | 02/16 | 02/16 | | |
NCT01864070: Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease |
|
|
| Withdrawn | 1 | 0 | US | TheraSphere, Everolimus, Afinitor, Zortress, RAD001, Phone Call | M.D. Anderson Cancer Center, BTG International Inc., Novartis Pharmaceuticals | Liver Cancer | 05/18 | | | |
